The FDA has outlined how developers of drugs targeting rare pediatric diseases can streamline their clinical development programs by collaborating. Officials want drug developers to consider teaming up to test multiple candidates in single trials, thereby cutting the number of patients who need to receive placebos.
Using Gaucher disease as an example, the FDA’s draft guidance (PDF) shows how companies can team up and run multidrug clinical trials. These studies would enable multiple experimental candidates to be compared against a single control group, increasing the proportion of patients in active arms.
Other sections of the guidance propose the use of modeling and simulation to predict the effect of a drug in children based on prior performance in adults. Collectively, the FDA sees the proposals streamlining the development of drugs to treat rare pediatric diseases.
“The FDA has drafted an approach to pediatric rare disease drug development that could eliminate the need for certain clinical studies and, when pediatric clinical studies are needed, could reduce the total number of patients who would receive a placebo instead of a potentially helpful drug,” Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research, said in a statement.
The genesis of the document dates back to 2011, when the FDA began working with the European Medicines Agency (EMA) to create a roadmap for the development of Gaucher disease drugs. That resulted in a guidance document that was released for public comment in 2014 and adopted (PDF) by the EMA earlier this year. It has now led to the publication of the draft FDA guidance.
Woodcock and her colleagues have copied large sections of the Gaucher guidance word for word but have extended its scope beyond the condition. In its new form, the FDA guidance proposes extending the principles underpinning the Gaucher development model to other diseases.
The guidance is still in a draft form and is open for comment for 60 days.
By Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
